

**DATES AND TIME:** Tuesday, March 3, 1998 at 10:00 a.m.

**PLACE:** 999 E Street, N.W., Washington, D.C.

**STATUS:** This meeting will be closed to the public.

**TIMES TO BE DISCUSSED:**

Compliance matters pursuant to 2

U.S.C. § 437g.

Audits conducted pursuant to 2 U.S.C.

§ 437g, § 438(b), and Title 26, U.S.C.

Matters concerning participation in civil actions or proceedings or arbitration.

Internal personnel rules and procedures or matters affecting a particular employee.

**DATE AND TIME:** Thursday, March 5, 1998 at 2:00 p.m.

**PLACE:** 999 E Street, N.W., Washington, D.C. (ninth floor).

**STATUS:** This meeting will be open to the public.

**ITEMS TO BE DISCUSSED:**

Correction and Approval of Minutes. Advisory Opinion 1997-28: W. Ben Bius.

Advisory Opinion 1998-02: Reform Party of the United States of America, by Russell J. Verney, Chairman.

Advisory Opinion 1998-03: Reform Party of Idaho, by Gary G. Allen, Chairman.

Audit: San Diego Host Committee/Sail to Victory '96 (continued from meeting of February 26, 1998).

Audit: Committee on Arrangements for the 1996 Republican National Convention (continued from meeting of February 26, 1998).

Legislative Recommendation—1998 (continued from Meeting of February 26, 1998).

Administrative Matters.

**PERSON TO CONTACT FOR INFORMATION:**

Mr. Ron Harris, Press Officer, Telephone: (202) 219-4155.

**Marjorie W. Emmons,**

*Secretary of the Commission.*

[FR Doc. 98-5083 Filed 2-24-98; 12:12 pm]

BILLING CODE 6715-01-M

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

**Joint Meeting of the Dermatologic and Ophthalmic Drugs Subcommittee and the Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

This notice announces a forthcoming meeting of public advisory committees of the Food and Drug Administration (FDA). The meeting will be open to the public.

*Name of Committees:* Joint meeting of the Dermatologic and Ophthalmic Drugs Subcommittee and the Endocrinologic and Metabolic Drugs Advisory Committee.

*General Function of the Committees:* To provide advice and recommendations to the agency on FDA regulatory issues.

*Date and Time:* The meeting will be held on March 11, 1998, 8 a.m. to 5 p.m.

*Location:* Holiday Inn, Walker Room, Two Montgomery Village Ave., Gaithersburg, MD.

*Contact Person:* Tracy Riley or Kathleen R. Reedy, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-5455, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), codes 12534 and 12536. Please call the Information Line for up-to-date information on this meeting.

*Agenda:* The committee will discuss scientific clinical trial design for products intended for the treatment of diabetic retinopathy.

*Procedure:* Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by March 4, 1998. Oral presentations from the public will be scheduled between approximately 8 a.m. and 8:30 a.m., and between approximately 1 p.m. and 1:30 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before March 4, 1998, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

FDA regrets that it was unable to publish this notice 15 days prior to the joint meeting of the Dermatologic and Ophthalmic Drugs Subcommittee and the Endocrinologic and Metabolic Drugs Advisory Committee. Because the agency believes there is some urgency to bring this issue to public discussion and qualified members of the Dermatologic and Ophthalmic Drugs Subcommittee and the Endocrinologic and Metabolic

Drugs Advisory Committee were available at this time, the Commissioner concluded that it was in the public interest to hold this meeting even if there was not sufficient time for the customary 15-day public notice.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: February 20, 1998.

**Michael A. Friedman,**

*Deputy Commissioner for Operations.*

[FR Doc. 98-5050 Filed 2-24-98; 11:42 am]

BILLING CODE 4160-01-F

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

**Vaccines and Related Biological Products Advisory Committee; Notice of Meeting**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

*Name of Committee:* Vaccines and Related Biological Products Advisory Committee.

*General Function of the Committee:*

To provide advice and recommendations to the agency on FDA regulatory issues.

*Date and Time:* The meeting will be held on March 23, 1998, 7:45 a.m. to 6:20 p.m.

*Location:* Ramada Inn, Embassy Ballroom, 8400 Wisconsin Ave., Bethesda, MD.

*Contact Person:* Nancy T. Cherry or Denise H. Royster, Center for Biologics Evaluation and Research (HFM-21), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301-827-0314, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12391. Please call the Information Line for up-to-date information on this meeting.

*Agenda:* The committee will: (1) Discuss scientific and ethical considerations of a human challenge model using virulent *Salmonella typhi* bacteria; (2) complete recommendations pertaining to the influenza virus vaccine formulation for 1998 and 1999; and (3) hear short briefings on research programs in the Laboratories of DNA Viruses, Hepatitis Viruses, and Bacterial Polysaccharides.